Shanghai Junshi Biosciences Co., Ltd. (USD) Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of various medicinal products. Primarily operating within the People's Republic of China, the company's research and development efforts are concentrated on a diverse range of disease areas, including oncology (cancer), metabolic conditions, autoimmune disorders, neurological ailments, and infectious diseases. Its flagship commercial offering is JS001, known by the brand name TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for treating multiple cancer indications, such as melanoma (including mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond its marketed product, Junshi Biosciences maintains a comprehensive pipeline of investigational therapies. These include UBP1211, a biosimilar of Humira, slated for conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Also under development are JS002, a recombinant humanized anti-PCSK9 monoclonal antibody targeting hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Additional development candidates feature JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, an injectable recombinant humanized anti-IL-17A monoclonal antibody. The company has established significant collaborations, including an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Furthermore, it has partnered with Coherus Biosciences, Inc. for the development and commercialization of toripalimab, which is Junshi Biosciences' proprietary anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. is headquartered in Shanghai, People's Republic of China.

Shanghai Junshi Biosciences Co., Ltd. (USD) Active

Building 7, Shanghai, CN, 200126

Stock Price USD

Price Change

Last Dividend USD

SHJBF's stock peer is AKBLF (ALK-Abelló A/S)

SHJBF's stock peer is CAMRF (Camurus AB)

SHJBF's stock peer is CLCGY (Clicks Group Limited)

SHJBF's stock peer is CSMYF (COSMOS Pharmaceutical Corporation)

SHJBF's stock peer is FLMNY (Fielmann Group AG)

SHJBF's stock peer is GEDSF (Gedeon Richter PLC)

SHJBF's stock peer is GNNSF (Genscript Biotech Corporation)

SHJBF's stock peer is INCPF (InnoCare Pharma Limited)

SHJBF's stock peer is LABFF (Laboratorios Farmaceuticos Rovi, S.A.)

SHJBF's stock peer is ZLDPF (Zealand Pharma A/S)

Healthcare Biotechnology

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of various medicinal products. Primarily operating within the People's Republic of China, the company's research and development efforts are concentrated on a diverse range of disease areas, including oncology (cancer), metabolic conditions, autoimmune disorders, neurological ailments, and infectious diseases. Its flagship commercial offering is JS001, known by the brand name TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for treating multiple cancer indications, such as melanoma (including mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond its marketed product, Junshi Biosciences maintains a comprehensive pipeline of investigational therapies. These include UBP1211, a biosimilar of Humira, slated for conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Also under development are JS002, a recombinant humanized anti-PCSK9 monoclonal antibody targeting hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Additional development candidates feature JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, an injectable recombinant humanized anti-IL-17A monoclonal antibody. The company has established significant collaborations, including an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Furthermore, it has partnered with Coherus Biosciences, Inc. for the development and commercialization of toripalimab, which is Junshi Biosciences' proprietary anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. is headquartered in Shanghai, People's Republic of China.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“NEOTORCH”, NCT04158440) of the company's product toripalimab in combination with platinum-containing doublet chemotherapy as perioperative treatment for resectable stage II-III non-small cell lung cancer (“NSCLC”) patients has finished its final analysis. The primary endpoints of event-free survival (“EFS”) and major pathological response (“MPR”) rate in the stage II-III population, as well as the MPR rate in the stage III population, met the pre-defined efficacy boundary.

2026-05-26 21:18:00

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J

2026-04-20 17:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions